Objective: Motivational interviewing (MI) is an effective intervention for improving health behavior in a number of domains, and evidence suggests that it may be useful for promoting oral health. The current pilot study was designed to provide initial evidence that, compared with a didactic control intervention, a brief MI-based intervention (BMI) delivered by dental practitioners can yield greater improvements in oral hygiene, health-care utilization, and health outcomes in a population at heightened risk for oral disease.
Method: Either the control intervention or BMI, delivered by a dentist or a dental hygienist, was randomly assigned to 60 individuals in inpatient treatment for alcohol-use disorders. Data were obtained by self-report and by examination at baseline and 4-, 12-, and 24-week follow-up assessments.
Results: BMI participants reported significantly more frequent toothbrushing during follow-up than control participants. No other significant effects were found.
Conclusion: These findings indicate that a brief intervention using MI methods can be delivered by dental professionals and has potential utility for promoting improved oral hygiene. Additional research to investigate and further develop MI's potential for promoting oral health appears warranted.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4095892 | PMC |
http://dx.doi.org/10.1037/a0033153 | DOI Listing |
Acta Odontol Scand
January 2025
CHU de Bordeaux, Pôle de Médecine et Chirurgie Bucco-Dentaire, F-33000 Bordeaux, France; Univ. Bordeaux, Oral Health Department, F-33000 Bordeaux, France.
Objective: To describe the oral health status of patients with obesity and to explore the socio-demographic characteristics, comorbidities, lifestyle habits (tobacco, alcohol, sweet/acidic diet), and saliva parameters most associated with the dental caries experience. Material and methods: We conducted a cross-sectional analysis of 204 patients' data with obesity attending a therapeutic education programme. Caries experience (number of decayed, missing, and filled teeth [DMFT]), periodontal status, oral hygiene, occlusal tooth wear, masticatory inefficiency, and saliva parameters were recorded.
View Article and Find Full Text PDFThis study aimed to gain knowledge of general oral health preventive measures with a specific focus on root caries preventive measures for patients ≥65 years old, performed by Norwegian dental hygienists in public and private dental health services. A secondary aim was to investigate differences and challenges in prevention practices. Materials and methods: An electronic survey was conducted among the sample in 2022.
View Article and Find Full Text PDFJAMA Neurol
January 2025
Takeda Development Center Americas, Inc, Cambridge, Massachusetts.
Importance: Fall risk and cognitive impairment are prevalent and burdensome in Parkinson disease (PD), requiring efficacious, well-tolerated treatment.
Objective: To evaluate the safety and efficacy of TAK-071, a muscarinic acetylcholine M1 positive allosteric modulator, in participants with PD, increased fall risk, and cognitive impairment.
Design, Setting, And Participants: This phase 2 randomized double-blind placebo-controlled crossover clinical trial was conducted from October 21, 2020, to February 27, 2023, at 19 sites in the US.
JAMA
January 2025
Department of Health Sciences, Faculty of Science, Vrije Universiteit Amsterdam, Amsterdam Public Health Research Institute, Amsterdam, the Netherlands.
Importance: Metformin and glyburide monotherapy are used as alternatives to insulin in managing gestational diabetes. Whether a sequential strategy of these oral agents results in noninferior perinatal outcomes compared with insulin alone is unknown.
Objective: To test whether a treatment strategy of oral glucose-lowering agents is noninferior to insulin for prevention of large-for-gestational-age infants.
Background: Ruxolitinib cream has demonstrated anti-inflammatory and antipruritic activity and was well tolerated in a phase 3 study in patients aged 2-11 years with mild to moderate atopic dermatitis (AD).
Objective: This study examined the safety, tolerability, pharmacokinetics, efficacy, and quality of life (QoL) with ruxolitinib cream under maximum-use conditions and with longer-term use.
Methods: Eligible patients were aged 2-11 years with moderate to severe AD [Investigator's Global Assessment (IGA) score 3-4], and ≥ 35% affected body surface area (BSA).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!